LSE company dividends information has been updated. You can find this is in the menu on any Quote page. ADVFN team.


Roquefort Therapeutics Plc

0.00 (0.0%)
Share Name Share Symbol Market Type Share ISIN Share Description
Roquefort Therapeutics Plc LSE:ROQ London Ordinary Share GB00BMDQ2T15 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 6.75 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Cmp Integrated Sys Design 0.00 -0.92 -1.30 - 4.85
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 6.75 GBX

Roquefort Therapeutics (ROQ) Latest News

Roquefort Therapeutics (ROQ) Discussions and Chat

Roquefort Therapeutics Forums and Chat

Date Time Title Posts
13/5/202322:08Roquefort a potentially exploding 2022 bio tech stock....61
22/12/202113:19ROQ - Watch the pumpers36

Add a New Thread

Roquefort Therapeutics (ROQ) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Roquefort Therapeutics (ROQ) Top Chat Posts

Top Posts
Posted at 03/3/2023 08:45 by the chairman elect
which leads one to believe that potentially ROQ could go on to double or even treble in value from here
Posted at 03/3/2023 08:44 by the chairman elect
The ROQ chart looks like a coiled spring....
Posted at 24/1/2023 08:00 by the chairman elect
Roquefort Therapeutics plc / LSE:ROQ

MDK Oncology Antibodies Demonstrate In-Vivo Safety

Development milestone achieved

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high growth, high value oncology market is pleased to announce the ROQ-A1 and ROQ-A2 Midkine ("MDK") antibody programs, targeting metastatic breast cancer and metastatic lung cancer, have successfully demonstrated in vivo safety in pre-clinical development programs carried out by leading cancer research groups.

As stated in the Company's announcement of 9 January 2023, Roquefort Therapeutics has recently signed partnership agreements and commenced pre-clinical development programs with leading academic cancer research groups at the Olivia Newton-John Cancer Research Institute (La Trobe University), Lowry Cancer Research Centre (University of New South Wales), Hawkins Laboratory Biochemistry and Genetics (La Trobe University) and the School of Medical Sciences (University of Sydney).

ROQ-A1 and ROQ-A2 are the latest patented humanised antibody medicines designed by Roquefort Therapeutics to target the novel MDK target prevalent in hard-to-treat cancers. In laboratory experiments, ROQ-A1 and ROQ-A2 bind highly specifically to the MDK receptors in cancer cells to kill cancers in vitro.

The MDK antibody programs targeting metastatic breast cancer and metastatic lung cancer commenced in Q4 2022 at La Trobe University, Melbourne in the Olivia Newton-John Cancer Research Institute and Hawkins Laboratory respectively and have now successfully reached the first pre-clinical drug development milestone. Metastatic breast cancer and metastatic lung cancer were chosen because of high patient mortality rates (~70% at five years) and prevalence of resistant MDK subtypes which can reduce effectiveness of existing therapies. Therefore, Roquefort Therapeutics is pleased that both ROQ-A1 and ROQ-A2 have demonstrated a good safety profile in validated in vivo models. These milestones were completed on schedule and within budget.

Both MDK antibody programs will now progress into in vivo pre-clinical efficacy studies to assess cancer killing ability in primary and metastatic breast cancer and lung cancer. The Company will update the market on the results of these efficacy studies as they progress.

Ajan Reginald, Chief Executive Officer of Roquefort Therapeutics, said:

"We have started 2023 with significant momentum successfully completing these initial pre-clinical development milestones on schedule and within budget. The ROQ-A1 and ROQ-A2 antibodies are valuable assets that fit the established Big Pharma paradigm of treating cancer with novel antibody therapeutics. Therefore, we are pleased that both programs have shown the good safety profile that is particularly attractive for innovative cancer medicines targeting novel targets such as Midkine. Both programs will now progress rapidly into in vivo pre-clinical efficacy testing. The siRNA, MK cell therapy and Midkine oligonucleotide programs are also progressing well and are expected to complete development milestones in Q1, which we will update the market on in due course."

Posted at 16/9/2022 07:40 by the chairman elect
RNSs out @ ROQ
Posted at 08/2/2022 15:00 by the chairman elect
ROQ starting to stir
Posted at 19/1/2022 09:55 by the chairman elect
Welcome to one and all. Please feel free to TICK UP all posts plus the header. As a FYI my share price target for ROQ is that during 2022 it will hit 50p+
Posted at 23/12/2021 14:23 by seagreen
Available at a smidge over the fund raise price now as quite a lot of bored people have raised the white flag. If there was a genuine chance of Midkine inhibitting Covid then it could go billy bonkers. Otherwise the main targeted ailments are still very very exciting, if it can be proven. May be life changing to many.

Anyway dded a smidge as my new issue quantity seems to have been shaved back.

Posted at 22/12/2021 09:10 by the chairman elect
ROQ has the potential in the NY to go on and hit 50p+
Posted at 22/12/2021 09:05 by the chairman elect
Perhaps a new thread for ROQ with charts is required?
Posted at 22/12/2021 08:35 by the chairman elect
Dunno but do know that ROQ has the potential in the NY to go on and hit 50p+
Roquefort Therapeutics share price data is direct from the London Stock Exchange
Your Recent History
Roquefort ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230602 21:33:18